A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1

Status:	Terminated
Conditions:	HIV / AIDS
Therapuetic Areas:	Immunology / Infectious Diseases
Healthy:	No
Age Range:	18 - Any
Updated:	6/21/2017
Start Date:	July 21, 2004
End Date:	July 16, 2005

The main objective of this study is to compare the safety and efficacy of an enfuvirtide
containing regimen to a nucleoside combination regimen. Resistance information will also be
collected.

Inclusion Criteria:

- CD4 cell count greater than 50 cells/mm^3

- HIV-1 RNA viral load greater than or equal to 5000 copies/mL

- Patients must be HIV treatment experienced

- Patients diagnosed with HIV-1 infection

Exclusion Criteria:

- Female patients must not be able to have children or must be under effective
contraceptives

- Female patients who are pregnant

- Have taken enfuvirtide and/or T-1249 before

- Have serious kidney problems

- Alcohol and/or drug abuse

- Have had an organ transplant

We found this trial at

sites

Clinical Trial Facility in Washington, D.C. District of Columbia

Washington, D.C., District of Columbia

from

Washington, D.C.,